Rattay Bernd, Benndorf Ralf A
Department of Clinical Pharmacy and Pharmacotherapy, Institute of Pharmacy, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany.
Front Pharmacol. 2021 Aug 13;12:727717. doi: 10.3389/fphar.2021.727717. eCollection 2021.
Drug-induced agranulocytosis is a life-threatening side effect that usually manifests as a severe form of neutropenia associated with fever or signs of sepsis. It can occur as a problem in the context of therapy with a wide variety of drug classes. Numerous drugs are capable of triggering the rare idiosyncratic form of agranulocytosis, which, unlike agranulocytosis induced by cytotoxic drugs in cancer chemotherapy, is characterised by "bizzare" type B or hypersensitivity reactions, poor predictability and a mainly low incidence. The idiosyncratic reactions are thought to be initiated by chemically reactive drugs or reactive metabolites that react with proteins and may subsequently elicit an immune response, particularly directed against neutrophils and their precursors. Cells or organs that exhibit specific metabolic and biotransformation activity are therefore frequently affected. In this review, we provide an update on the understanding of drug-induced idiosyncratic agranulocytosis. Using important triggering drugs as examples, we will summarise and discuss the chemical, the biotransformation-related, the mechanistic and the therapeutic basis of this clinically relevant and undesirable side effect.
药物性粒细胞缺乏症是一种危及生命的副作用,通常表现为与发热或败血症体征相关的严重中性粒细胞减少症。它可能作为多种药物治疗过程中的一个问题出现。许多药物能够引发罕见的特异质性粒细胞缺乏症,与癌症化疗中细胞毒性药物诱导的粒细胞缺乏症不同,其特征为“怪异”的B型或超敏反应、预测性差且发病率主要较低。特异质性反应被认为是由化学反应性药物或反应性代谢产物引发的,这些物质与蛋白质发生反应,随后可能引发免疫反应,特别是针对中性粒细胞及其前体的免疫反应。因此,具有特定代谢和生物转化活性的细胞或器官经常受到影响。在本综述中,我们提供了对药物性特异质性粒细胞缺乏症认识的最新情况。以重要的引发药物为例,我们将总结并讨论这种临床相关且不良副作用的化学、生物转化相关、机制及治疗基础。